135 citations
,
August 1994 in “Clinical Endocrinology” In this study of women with hirsutism or androgenic alopecia, diverse underlying endocrine disorders including polycystic ovaries and various enzyme deficiencies were detected, often associated with elevated testosterone levels.
January 2004 in “Side effects of drugs annual” Certain skin drugs and topical agents, including some natural extracts and fragrances, can cause allergic reactions. Some hair dyes and extensions, as well as minoxidil, a hair growth treatment, can also cause allergies. Botulinum toxin A can effectively reduce sweat but may have temporary side effects.
4 citations
,
January 2024 in “Allergy” This study indicates that individuals exposed to PPD mount varying immune responses, with either tolerance, subclinical inflammation, or allergy, suggesting no true non-responders to PPD.
September 2017 in “Pediatric Dermatology” No results are reported in this correspondence published in Pediatric Dermatology, as it responds to prior communication about contact dermatitis related to alopecia and hyperpigmentation.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.
January 2026 in “JCEM Case Reports” The researchers reported a case of a 51-year-old woman with primary hypothyroidism who developed anaphylaxis to intravenous levothyroxine after being unresponsive to oral formulations, highlighting potential allergic reactions to IV treatments in such patients.
2 citations
,
January 2014 in “Elsevier eBooks” This review discusses drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms, highlighting clinical features, potential viral reactivations, and treatment, but reports no new clinical findings.
1 citations
,
May 2022 in “European Journal of Dermatology” This study found that while no predictive factors for response to vismodegib were identified, longer treatment duration was associated with a lower risk of relapse in basal cell carcinoma patients.
1 citations
,
February 1976 in “JAMA” In this article, the author reports a case where hemiballismus was almost completely suppressed within 48 hours of starting haloperidol therapy, suggesting a therapeutic response to the drug.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This presentation argues that post-exposure syndromes like PSSD and Long COVID form a coherent group of conditions driven by complex interactions in high-dimensional state spaces rather than singular molecular pathways.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study examines how conditions like PSSD, Long COVID, and ME/CFS form a "Post-Exposure Syndromes" family, initiated by transient exposures but persisting due to complex state-space dynamics, and suggests improving pharmacovigilance to better address and understand these persistent syndromes.
April 2023 in “Journal of Investigative Dermatology” This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.
33 citations
,
October 2018 in “BMJ Case Reports” This case report describes a 6-year-old who developed autoimmune conditions including type III polyglandular autoimmune syndrome following drug-induced hypersensitivity syndrome, prompting an investigation into associated triggering factors.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.
2 citations
,
June 2020 in “Clinical & experimental allergy/Clinical and experimental allergy” This study found that the implementation of a streamlined referral pathway improved the rate of anaphylaxis referrals from an emergency department to a specialized allergy service from 0% in 2007 to 44% in 2016.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.
14 citations
,
April 2020 in “Journal of the American Academy of Dermatology” Viral reactivation is rare at the time of DRESS diagnosis in the U.S.
This abstract is a navigation and policy notice for a website and does not contain any research findings.
1 citations
,
March 2011 in “Hospital Pharmacy” This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but it presents no new research findings.
6 citations
,
February 2016 in “British Journal of Dermatology” A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
February 2023 in “European Journal of Medical Research” This study identified several drugs that may be potential candidates for repurposing as anti-hyperhidrosis treatments, based on their association with hypohidrosis or anhidrosis in the FDA Adverse Event Reporting System.
20 citations
,
August 2008 in “Journal of Medical Case Reports” This case report describes a probable hypersensitivity reaction to a single intravenous dose of ondansetron, highlighting the need for cautious use, especially in outpatient settings.
82 citations
,
September 2011 in “Quality of Life Research” This review discusses the selection of recall periods for patient-reported outcome measures based on disease attributes, highlighting that inappropriate recall periods can misestimate symptom burden and patient health states; it reports no new findings.
13 citations
,
April 2023 in “Nature communications” In this study, researchers used EHR data from two large PCORnet networks to identify a range of long COVID diagnoses, highlighting varying post-acute risks across populations in NYC and Florida.
3 citations
,
January 2008 in “Journal of the American Academy of Dermatology” A patient's skin rash did not affect the area where a previous viral rash was healing, suggesting a rare immune response.
11 citations
,
October 2003 in “Postgraduate Medical Journal” This study described four cases of delayed diagnosis of Cushing’s syndrome, highlighting that increased clinical awareness and screening could reduce its associated morbidity and mortality.
24 citations
,
October 1995 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.
48 citations
,
January 2011 in “Hormone Research in Paediatrics” This review discusses the molecular basis and clinical implications of primary generalized glucocorticoid resistance and hypersensitivity, attributing them to mutations in the human glucocorticoid receptor gene, and reports no new clinical findings.
8 citations
,
November 2011 in “Journal of Medical Case Reports” This case report describes a 23-year-old Asian woman with fluoxetine non-responsive trichotillomania who showed significant improvement with bupropion and cognitive behavior therapy, though confirmation in larger trials is needed.